alpha /beta - and gamma /delta TCR+ lymphocyte infiltration in necrotising choroidal melanomas

Bialasiewicz, A. A.; Ma, Jin-Xue; Richard, Gisbert

doi:10.1136/bjo.83.9.1069

Cited by 32 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7] Vd1 1 cd TILs are present in melanoma, and the infiltration of these cells into necrotizing melanoma correlates with survival. 17 Orthotopic xenografts of the HT29 colon cancer cells in mice infused with human TCRVd2 2 cd T lymphocytes also carried cd TILs that impaired tumor development. 18 In prostate and breast tumors, however, Vd1 1 cd TILs are rather immunosuppressive for dendritic cells and T cells 19 and favor the growth of the tumor through IL-10 release.…”

Section: Rationale For Harnessing CD Cells In Cancer Immunotherapymentioning

confidence: 99%

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

et al. 2012

View full text Add to dashboard Cite

During the last several years, research has produced a significant amount of knowledge concerning the characteristics of human cd T lymphocytes. Findings regarding the immune functions of these cells, particularly their natural killer cell-like lytic activity against tumor cells, have raised expectations for the therapeutic applications of these cells for cancer. Pharmaceutical companies have produced selective agonists for these lymphocytes, and several teams have launched clinical trials of cd T cell-based cancer therapies. The findings from these studies include hematological malignancies (follicular lymphoma, multiple myeloma, acute and chronic myeloid leukemia), as well as solid tumors (renal cell, breast and prostate carcinomas), consisting of samples from more than 250 patients from Europe, Japan and the United States. The results of these pioneering studies are now available, and this short review summarizes the lessons learned and the role of cd T cell-based strategies in the current landscape of cancer immunotherapies.

show abstract

Section: Rationale For Harnessing CD Cells In Cancer Immunotherapymentioning

confidence: 99%

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In a pilot study, we recently identified the frequency of circulating Vδ1+ γδ T-cells as a negative prognostic marker candidate for advanced melanoma patients (31). In contrast, tumor-infiltrating Vδ1+ cells were reported to have a positive impact on survival of melanoma patients (32). Vδ2+ cells were decreased in the peripheral blood and had impaired functionality in melanoma compared to healthy controls in a study by Petrini et al (29).…”

Section: Introductionmentioning

confidence: 99%

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

Wistuba‐Hamprecht

Martens

Haehnel

et al. 2016

European Journal of Cancer

View full text Add to dashboard Cite

Human γδ T-cells possess regulatory and cytotoxic capabilities, and could potentially influence the efficacy of immunotherapies. We analyzed the frequencies of peripheral γδ T-cells, including their most prominent subsets (Vδ1+ and Vδ2+ cells) and differentiation-states in 109 melanoma patients and 109 healthy controls. We additionally analyzed the impact of γδ T-cells on overall survival (OS) calculated from the first dose of ipilimumab in melanoma patients. Higher median frequencies of Vδ1+ cells and lower median frequencies of Vδ2+ cells were identified in patients compared to healthy subjects (Vδ1+: 30% vs. 15%, Vδ2+: 39% vs. 64%; both p<0.001). Patients with higher frequencies of Vδ1+ cells (≥30%) had poorer OS (p=0.043) and a Vδ1+ differentiation-signature dominated by late-differentiated phenotypes. In contrast, higher frequencies of Vδ2+ cells (≥39%) were associated with longer survival (p=0.031) independent of the M category or lactate dehydrogenase (LDH) level. Patients with decreasing frequencies of Vδ2+ cells under ipilimumab treatment had worse OS and a lower rate of clinical benefit than patients without such decreases. Therefore, we suggest frequencies of both Vδ1+ and Vδ2+ cells as candidate biomarkers for outcome in melanoma patients following ipilimumab. Further studies are needed to validate these results and to clarify whether they represent prognostic associations or whether γδ T-cells are specifically and/or functionally linked to the mode of action of ipilimumab.

show abstract

“…gd TILs isolated in various types of cancer, including colorectal, breast, prostate, ovarian and RCC [17,24,25], recognize and kill both the autologous tumor and a broad range of related tumors, presumably via the recognition of shared stress-related ligands, but do not kill nontransformed cells [17,25]. The infiltration of Vg1 and Vd1 gd T cells into necrotizing melanomas (NMMs) significantly correlates with increased survival [26], whereas intratumoral gd T cell infiltration in RCC tumors does not [27]. These studies suggest that gd T cell infiltration might be beneficial; however, the immunoregulatory properties of gd T cells should not be ignored [28].…”

mentioning

confidence: 98%

Harnessing γδ T cells in anticancer immunotherapy

Hannani¹,

Ma²,

Yamazaki³

et al. 2012

Trends in Immunology

View full text Add to dashboard Cite

γδ T lymphocytes are involved in the stress response to injured epithelia and in tissue homeostasis by limiting the dissemination of malignant or infected cells and by regulating the nature of the subsequent adaptive immune response. γδ T cells have potent MHC-unrestricted cytotoxicity, a high potential for cytokine release and broad-spectrum recognition of cancer cells, and as such, are attractive effectors for cancer immunotherapy. Current expectations are going beyond ex vivo manipulation of the Vγ9Vδ2 T subset, and target novel γδ T cell subsets, properties or receptors, to harness these unconventional T lymphocytes against cancer. This Opinion article discusses novel aspects of γδ T cell function during the course of anticancer therapies, as well as new avenues for their clinical implementation.

show abstract

alpha /beta - and gamma /delta TCR+ lymphocyte infiltration in necrotising choroidal melanomas

Cited by 32 publications

References 22 publications

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

Harnessing γδ T cells in anticancer immunotherapy

Contact Info

Product

Resources

About